Goldman Sachs
UPB

Goldman Sachs’s Upstream Bio Inc UPB Stock Holding History

Goldman Sachs’s Portfolio UPB Stock Details UPB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.71M Sell
246,917
-69,670
-22% -$584K ﹤0.01% 4807
2026
Q1 		$2.85M Sell
316,587
-16,894
-5% -$304K ﹤0.01% 4212
2025
Q4 		$9.05M Buy
333,481
+110,267
+49% +$2.74M ﹤0.01% 3188
2025
Q3 		$4.2M Buy
+223,214
New +$3.47M ﹤0.01% 3803
2025
Q2 		– Sell
-32,955
Closed -$202K – 6534
2025
Q1 		$202K Sell
32,955
-11,535
-26% -$110K ﹤0.01% 5640
2024
Q4 		$731K Buy
+44,490
New +$993K ﹤0.01% 5033

Other funds holding UPB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Goldman Sachs's UPB Position: Q2 2026 in Review

Goldman Sachs reduced its Upstream Bio Inc (UPB) stake by 22% in Q2 2026, selling an estimated $584K and leaving 246,917 shares worth $1.71M. The position accounts for ﹤0.01% of the portfolio, ranked #4807.

Goldman Sachs first reported a position in UPB in Q4 2024 and has held it in 6 quarters since. The position peaked at $9.05M in Q4 2025. 148 funds tracked by Wall St. Rank hold UPB as of Q2 2026.

  • Goldman Sachs held 246,917 shares of Upstream Bio Inc worth $1.71M as of Q2 2026.
  • Goldman Sachs sold 69,670 Upstream Bio Inc shares in Q2 2026, an estimated $584K.
  • Upstream Bio Inc made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4807 holding.
  • Goldman Sachs first reported a position in Upstream Bio Inc in Q4 2024 and has held it in 6 quarters since.
  • Goldman Sachs's Upstream Bio Inc position peaked at $9.05M in Q4 2025.
  • 148 funds tracked by Wall St. Rank held Upstream Bio Inc as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.